Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1

Silvia C. W. Ling, 1,6 Edwin K. K. Lau, 1 Ammira Al-Shabeeb, 1 Angela Nikolic, 1 Albert Catalano, 2 Harry Iland, 2 Noemi Horvath, 3 P. Joy Ho, 2 Simon Harrison, 4,5 Shaun Fleming, 4 Douglas E. Joshua, 1,2 and John D. Allen 1

1Centenary Institute of Cancer Medicine and Cell Biology and the University of Sydney, Sydney, Australia; 2Institute of Haematology, Royal Prince Alfred Hospital, Sydney, Australia; 3Institute of Medical and Veterinary Sciences and the Royal Adelaide Hospital, Adelaide, Australia; 4Haematology Department, Peter MacCallum Cancer Centre, East Melbourne, Australia, and 5University of Melbourne, Parkville, Melbourne, Australia


Online Supplementary Figure S1. Unspliced and spliced XBP-1 in myeloma, lymphoma and solid cancers. (A) Proportions of unspliced and spliced XBP-1 mRNA in myeloma cell lines. Log-phase PCR products spanning the intron were quantified by polyacrylamide gel electrophoresis and densitometry, corrected by reference to standard ratios of unspliced:spliced cDNA templates. Each sample was amplified in duplicate. (B) For comparison, ratios of unspliced:spliced XBP-1 mRNA in a panel of non-myeloma cell lines were determined in the same manner.